Regulation of transepithelial ion transport by two different purinoceptors in the apical membrane of canine kidney (MDCK) cells.
1. The effect of extracellular nucleotides on the transepithelial ion transport of Madin Darby canine kidney cells (MDCK) was investigated. Cells were grown up to confluency on permeable supports and the short circuit current (ISC) was measured with an Ussing chamber-like mini-perfusion system. 2. Apical ATP stimulated a biphasic ISC increase consisting of a first rapid and transient peak followed by a broader one. 3. The first peak evoked by ATP was reversibly blocked by basilen blue (BB) in a concentration-dependent fashion, with an EC50 of 7.5 microM. 4. The P2 gamma receptor agonist, 2-methylthioATP (2-MeSATP) caused a single transient ISC increase that was completely blocked by pretreatment with BB. On the contrary, the P2x agonist, alpha, beta-methylene ATP (alpha, beta-meATP) was almost completely ineffective on ISC. UTP essentially induced a monophasic response the time-course of which resembled that of the second peak stimulated by ATP. The agonist potency order was 2-MeSATP > or = ATP >> UTP, alpha, beta-meATP for the first peak and UTP > or = ATP > 2-MeSATP > alpha, beta-meATP for the second peak. 5. Monolayer incubation with the membrane permeable calcium chelator [bis-o-aminophenoxy)-ethane-N,N,N',N',-tetraacetic acid, tetra(acetoximethyl)-ester] (BAPTA/AM) inhibited the ATP-evoked first peak. 6. The non-hydrolyzable ATP analogue, adenosine-5'-O-(3-thio)-trisphosphate (ATP-gamma-S) elicited a biphasic response similar to that of ATP. The P1 receptor agonist, 2-chloroadenosine and CGS-21680, were almost unable to induce an ISC increase.2+ increase. The second induces prostaglandin synthesis probably through a P2U receptor activation.
Zegarra-Moran
O
O
Laboratorio di Genetica Molecolare, 1st Giannina Gaslini, Genova, Italy.
Romeo
G
G
Galietta
L J
LJ
D000255:Adenosine Triphosphate / Q000031:analogs & derivatives / Q000494:pharmacology; D000818:Animals; D001693:Biological Transport, Active / Q000187:drug effects; D002460:Cell Line; D002712:Chlorides / Q000378:metabolism; D004285:Dogs; D004847:Epithelial Cells; D004848:Epithelium / Q000378:metabolism; D007213:Indomethacin / Q000494:pharmacology; D007473:Ion Channels / Q000187:drug effects / Q000378:metabolism; D007668:Kidney / Q000378:metabolism*; D009711:Nucleotides / Q000037:antagonists & inhibitors / Q000494:pharmacology; D018408:Patch-Clamp Techniques; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology; D058910:Purinergic P2 Receptor Agonists; D058919:Purinergic P2 Receptor Antagonists; D018048:Receptors, Purinergic P2 / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects; D014227:Triazines / Q000494:pharmacology
D002712:Chlorides; D007473:Ion Channels; D009711:Nucleotides; D011500:Protein Synthesis Inhibitors; D058910:Purinergic P2 Receptor Agonists; D058919:Purinergic P2 Receptor Antagonists; D018048:Receptors, Purinergic P2; D014227:Triazines; C012842:Cibacron Blue F 3GA; D000255:Adenosine Triphosphate; D007213:Indomethacin